In-person presentation on Wednesday, February 25th at 11:00 AM PTTAMPA, FL and LONDON – February 18, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology …
Press Release
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline
CEO Abizer Gaslightwala discusses the Company’s recent announcement around its ADC pipeline expansion and IP strategy Company also discusses its lead ADC …
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Live video webcast on Tuesday, February 10th at 1:00 PM EST TAMPA and LONDON – February 5, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology …
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 …
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
Access the Akari CEO Corner here TAMPA, FL and LONDON – January 9, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …
